Search Patents
-
Publication number: 20140343136Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.Type: ApplicationFiled: November 21, 2012Publication date: November 20, 2014Inventors: Angelo Antonio Izzo, Francesca Borelli, Stephen Wright
-
Patent number: 9421187Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.Type: GrantFiled: November 21, 2012Date of Patent: August 23, 2016Assignee: GW Pharma LimitedInventors: Angelo Antonio Izzo, Francesca Borrelli, Stephen Wright
-
Publication number: 20140107192Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: April 17, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Publication number: 20140378539Abstract: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.Type: ApplicationFiled: May 18, 2012Publication date: December 25, 2014Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Sabatino Maione, Francesco Rossi, Geoffrey Guy, Colin Stott, Tetsuro Kikuchi
-
Publication number: 20120046351Abstract: The invention is a product and a process wherein cannabinoids such as Medicinal ?9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are added to a foodstuff where the medicinal cannabis is not evenly distributed throughout the foodstuff where the food stuff contains a known weight of medicinal cannabis. Another provision of the invention is providing controlled amounts or ratios of ?9-THC as compared to CBD in or on a foodstuff.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Inventor: Andrew David Hospodor
-
Patent number: 11413266Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.Type: GrantFiled: September 29, 2016Date of Patent: August 16, 2022Assignee: GW Pharma LimitedInventors: Tamás Biró, Colin Stott, Vincenzo Di Marzo
-
Publication number: 20110021617Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.Type: ApplicationFiled: August 25, 2010Publication date: January 27, 2011Applicant: Nederlandse Organisatie voor Toegepast- Natuurwetenschappelijk Onderzoek TNOInventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
-
Patent number: 7807711Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.Type: GrantFiled: August 2, 2006Date of Patent: October 5, 2010Assignee: Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNOInventors: Henricus Adriaan A. J. Korthout, Kitty Catharina M. Verhoeckx, Rentje Frederik Witkamp, Robert Paul Doornbos, Mei Wang
-
Publication number: 20140221469Abstract: The present invention relates to the use of phytocannabinoids in the treatment of cancer. More particularly it relates to the use of phytocannabinoids in the treatment of tumour cell invasion and cell migration or metastases. Cancers, where invasion and cell migration plays a key role in prognosis include brain tumours, more particularly gliomas, and most particularly Glioblastoma multiforme (GBM) and breast cancers. The phytocannabinoids tetrahydrocannabivarin (THCV) and cannabidivarin (CBDV) alone or in combination with each other and/or other phytocannabinoids, particularly cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG) or their respective acids are of particular use.Type: ApplicationFiled: September 10, 2012Publication date: August 7, 2014Applicants: Otsuka Pharmaceutical Co., Ltd., GW Pharma LimitedInventors: Ruth Alexandra Ross, Daniela Parolaro
-
Publication number: 20110038958Abstract: The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.Type: ApplicationFiled: December 17, 2008Publication date: February 17, 2011Applicants: GW Pharma Limited, Otsuka Pharmaceutical Co., Ltd.Inventors: Tetsuro Kikuchi, Kenji Maeda, Geoffrey Guy, Philip Robson, Colin Stott
-
Publication number: 20030232101Abstract: In one aspect, the invention provides a method for preventing the transmission of HIV from one individual to another. In accordance with the method, a pharmacologically-acceptable composition including at least one resorcinol derivative compound and/or cannabinoid (e.g., cannabinol derivatives, &Dgr;8-THC derivatives, cannabichromene derivatives, cannabidiol derivatives, cannabigerol derivatives) (including combinations thereof) is administered topically to a first individual harboring HIV, or to a second individual at risk of infection with HIV, proximate in time with contact between the first individual and the second individual. The invention also provides topical formulations of at least one resorcinol and/or cannabinoid and water insoluble polymers as hydrogels.Type: ApplicationFiled: March 18, 2003Publication date: December 18, 2003Applicant: Immugen Pharmaceuticals, Inc.Inventor: Craig R. Travis
-
Publication number: 20120043242Abstract: The invention is a product and a process wherein Medicinal Delta-9 tetrahydrocannabinol (?9-THC) and potentially other cannabinoids (medicinal cannabis substances) associated with decarboxylated cannabis, including yet not necessarily limited to cannbidiols, and cannabigerol are rendered into a fatty foodstuff and then molded into a mold that also acts as a package. The best mode of the invention is a blister pack containing a plurality of voids or receptacles of desired sizes. A product that is characterized by a controlled amount of medicinal cannabis per unit volume of a fatty foodstuff base material is inserted into the mold, then cooled, and finally sealed. Each void or receptacle contains a known amount of medicinal cannabis that are independently dispensable.Type: ApplicationFiled: April 4, 2011Publication date: February 23, 2012Inventor: Andrew David Hospodor
-
Publication number: 20120095088Abstract: The invention is a product and a process wherein cannabinoids such as Medicinal ?9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are contained or processed into foodstuffs or medicinal compounds in controlled ways and with specific characteristics. First a medicinal substance with a known about of medicinal cannabis is mixed into a foodstuff such that the medicinal cannabis is distributed uniformly in the foodstuff. Foodstuffs consistent with this invention include baked goods, hard candies, ice cream, bases, ice cream, and yogurt. The product is characterized by a controlled amount of cannabinoids per unit volume of the foodstuff. Another provision of the invention is providing controlled amounts or ratios of ?9-THC as compared to CBD in a foodstuff.Type: ApplicationFiled: August 19, 2011Publication date: April 19, 2012Inventor: Andrew David Hospodor
-
Patent number: 6274635Abstract: The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.Type: GrantFiled: March 22, 2000Date of Patent: August 14, 2001Assignee: Immugen Pharmaceuticals Inc.Inventor: Craig A. Travis
-
Patent number: 10857107Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.Type: GrantFiled: January 31, 2018Date of Patent: December 8, 2020Assignee: GBS Global BioPharma, Inc.Inventors: Andrea Small-Howard, Helen Turner
-
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
Patent number: 6949582Abstract: A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.Type: GrantFiled: September 13, 2002Date of Patent: September 27, 2005Inventor: Walter H. Wallace